RNA Stock Summary and Trading Ideas (Avidity Biosciences | NASDAQ:RNA)

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Avidity Biosciences trades on the NASDAQ stock market under the symbol RNA.

As of February 27, 2026, RNA stock price declined to $14.75 with 4,624,351 million shares trading.

RNA has a beta of 1.65, meaning it tends to be more sensitive to market movements. RNA has a correlation of 0.03 to the broad based SPY ETF.

RNA has a market cap of $2.28 billion. This is considered a Mid Cap stock.

Last quarter Avidity Biosciences reported $12 million in Revenue and -$1.27 earnings per share. This beat revenue expectation by $10 million and missed earnings estimates by -$.19.

In the last 3 years, RNA traded as high as $73.06 and as low as $4.83.

The top ETF exchange traded funds that RNA belongs to (by Net Assets): VTI, VB, IWM, VXF, VBR.

RNA has underperformed the market in the last year with a price return of -49.3% while the SPY ETF gained +18.5%. RNA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -79.4% and -79.8%, respectively, while the SPY returned +1.2% and +0.6%, respectively.

RNA support price is $72.68 and resistance is $72.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNA shares will trade within this expected range on the day.